Background. Microvessel count (MVC) has been correlated with patient prognosis in hepatocellular carcinoma. We investigated whether MVC assessed by staining with CD34 antibody was associated with disease-free and overall survival in patients with metastatic liver cancer (MLC). Methods. We examined relationships between MVC and clinicopathologic factors or postoperative outcomes in 139 MLC patients who underwent hepatectomy between 1990 and 2006. CD34 expression was analyzed by the immunohistochemical method. Results. MVC was associated with fibrous pseudocapsular formation on histological examination. By means of the modern Japanese classification of liver metastasis, poorer survival was associated with higher score, poorly differentiated adenocarcinoma, higher preoperative carcinoembryonic antigen (CEA) level, fibrous pseudocapsular formation, and smaller surgical margin. Shorter diseasefree survival was associated with higher score when the Japanese classification of liver metastasis was used, multiple or bilobar tumor, regional lymph node metastasis in primary colon carcinoma, preoperative CEA level, fibrous pseudocapsular formation, and smaller surgical margin (\5 mm). Higher MVC (C406/mm 2 ) was associated with decreased disease-free and overall survival by univariate analysis (P = .034 and P = .021, respectively), and higher MVC represented an independently poor prognostic factor in overall survival by Cox multivariate analysis (risk ratio, 2.71; P = .023) in addition to histological differentiation. Conclusions. Tumor MVC seems to be a useful prognostic marker of MLC patient survival.
ABSTRACT
Background. Microvessel count (MVC) has been correlated with patient prognosis in hepatocellular carcinoma. We investigated whether MVC assessed by staining with CD34 antibody was associated with disease-free and overall survival in patients with metastatic liver cancer (MLC). Methods. We examined relationships between MVC and clinicopathologic factors or postoperative outcomes in 139 MLC patients who underwent hepatectomy between 1990 and 2006. CD34 expression was analyzed by the immunohistochemical method. Results. MVC was associated with fibrous pseudocapsular formation on histological examination. By means of the modern Japanese classification of liver metastasis, poorer survival was associated with higher score, poorly differentiated adenocarcinoma, higher preoperative carcinoembryonic antigen (CEA) level, fibrous pseudocapsular formation, and smaller surgical margin. Shorter diseasefree survival was associated with higher score when the Japanese classification of liver metastasis was used, multiple or bilobar tumor, regional lymph node metastasis in primary colon carcinoma, preoperative CEA level, fibrous pseudocapsular formation, and smaller surgical margin (\5 mm). Higher MVC (C406/mm 2 ) was associated with decreased disease-free and overall survival by univariate analysis (P = .034 and P = .021, respectively), and higher MVC represented an independently poor prognostic factor in overall survival by Cox multivariate analysis (risk ratio, 2.71; P = .023) in addition to histological differentiation. Conclusions. Tumor MVC seems to be a useful prognostic marker of MLC patient survival.
Hepatic resection is a useful option in the radical treatment of metastatic liver carcinoma (MLC). However, recurrence rates after resection remain high, limiting patient survival.
1,2 Some clinicopathologic factors in MLC-specifically, tumor recurrence and the biological characteristics of the tumor-provide useful information about tumor activity. [3] [4] [5] According to previous reports, good potential candidates for molecular markers and tumor biological factors in MLC patients include assessing lymphatic microvessel count (MVC) by immunohistochemical staining with CD34 antibody, doubling times, angiogenic factors, growth factors, abnormal expression of other oncogenes, and suppressor genes such as TP53, and carcinoembryonic antigen (CEA). [6] [7] [8] [9] [10] [11] The use of a combination of conventional clinicopathologic factors and tumor biology may improve our prognostic ability in patients who undergo hepatectomy for MLC and may contribute to a better staging system.
Tumor angiogenesis may be important in supporting tumor growth. 12 Metastatic liver cancer (MLC) also expresses angiogenic factors such as vascular endothelial growth factor (VEGF) and MVCs. 9, 13 Levels of these angiogenic factors may affect patient survival. 9, 13 Recent studies have shown that MVC in primary or metastatic liver carcinomas correlates with tumor aggressiveness and prognosis. [13] [14] [15] In a preliminary analysis with a small number of patients and a short follow-up period, we have shown that higher MVC by immunohistochemical staining with CD34 antibody is independently associated with poorer prognosis in MLC patients undergoing hepatic resection. 16, 17 On the basis of this prior work, we hypothesize that hypervascularity is a prognostic indicator of decreased survival in patients with MLC because it is associated with tumor growth and invasion. Patients with simultaneous liver metastasis who underwent resection of both the primary lesion and hepatectomy numbered 62 (45%). A total of 136 patients had a ChildPugh classification of A, and 3 patients (2%) had a ChildPugh classification of B. The operative procedures included hemihepatectomy or extended hemihepatectomy (n = 22), segmentectomy or sectionectomy (n = 85), and partial resection (n = 32). Radical hepatectomy was performed to remove hepatic tumor without leaving any residual tumor. All hepatic tumors were completely resected without macroscopic exposure of the amputated section to the remaining liver.
PATIENTS AND METHODS

Patients
Patients undergoing additional ablation therapy were excluded from our series. All in-hospital deaths were excluded, and only cancer-related death was included in our study. The median follow-up period after hepatic resection of MLC was 52 months, ranging between 22 and 159 months. We used the classification system of the Japanese Society for Cancer of the Colon and Rectum for clinicopathologic evaluation and the H classification of Japan to evaluate the stage of liver metastasis (Table 1) . 18 On the basis of our previous reports, postoperative survival in MLC patients with a surgical margin of \5 mm was much different from that in patients with a surgical margin of \5 mm, and a report by Kokudo et al. was referenced. 4 We therefore used a 5-mm surgical margin as a cutoff level in the present study as well. 16, 17 All study protocols were approved by the human ethics review board of our institution. Informed consent for data collection was obtained from each patient during this period. Anesthesia data and patient data were retrieved from the NUGSBS database.
Immunohistochemical Staining
Resected specimens were fixed in 10% formalin and embedded in paraffin. Thin sections (4 lm) were deparaffinized twice with xylene and rehydrated in a series of ethanol solutions (100%, 90%, and 80%). Sections were placed in .01 mol/l trisodium citrate dehydrate buffer (pH 6.0) and treated in a microwave oven for 10 min at 500 W. For CD34 staining, tissue sections were digested with .2% trypsin in .01 mol/l phosphate-buffered saline for 20 min at 37°C. 14, 15 The tissues were then immersed in 3% H 2 O 2 with distilled water for 10 min to inactivate endogenous peroxidases. After blocking nonspecific binding by normal goat serum, sections were incubated overnight at 4°C with mouse anti-monoclonal CD34 antibody (1:25; QB-END/10, Novocastra Laboratories, Newcastle, United Kingdom) as the primary antibody. This was followed by reaction with biotinylated anti-immunoglobulin and reagent with labeled streptavidinbiotin kit peroxidase (Dako, Carpinteria, CA). The peroxidase reaction was visualized with .01% H 2 O 2 and 3,3 0 -diaminobenzidine under light microscopy (9200 magnification). For MVC by CD34 staining, average count was determined in the five most vascular areas in the MLC examined at 9200 magnification. 14, 15 Two pathologists blindly assessed each slide, and a larger count was applied as representative data in the present study. The large difference of MVC over 50/mm 2 between pathologists by the recheck was not observed in the present series. Figure 1 shows the high and low MVC, respectively.
Statistical Analysis
Continuous data were expressed as mean ± standard deviation. Data from different groups were compared by one-way analysis of variance and examined by Student's t-test or Dunnett's multiple comparison test. For univariate analysis, categorical data were analyzed by Fisher's exact test. Disease-free and overall survival rates were calculated according to the Kaplan-Meier method, and differences between groups were tested for significance by the log rank test. Multivariate analysis was performed by proportional Cox hazard regression modeling. A two-tailed value of P \ .05 was considered statistically significant. All statistical analyses were performed by SAS software (SAS Institute, Cary, NC).
RESULTS
Among the 139 patients in the present study, overall 1-, 3-, and 5-year survival rates were 76%, 48%, and 36%, respectively, and median overall survival was 65 months. Disease-free 1-, 3-, and 5-year survival rates were 45%, 19%, and 14%, respectively, and median disease-free survival was 29 months. Of 100 patients (71.9%) who displayed tumor recurrence after hepatectomy, 21 (15.1%) received rehepatectomy and 79 (56.8%) received chemotherapy. Median MVC within the tumor area was 238/mm 2 , and this value was applied as the cutoff value. Table 2 shows the relationship between MVC and clinicopathologic features. MVC was statistically significantly higher in tumors with fibrous pseudocapsule formation compared with those tumors without this capsule. However, MVC was not associated with any other clinicopathologic factor, H classification, or postoperative recurrence rate. Table 3 shows the relationship between disease-free or overall survival and clinicopathologic factors, including MVC. Preoperative CEA level, H classification, number of tumors, tumor distribution, and MVC were related to disease-free survival. H classification, histological CEA carcinoembryonic antigen differentiation, fibrous pseudocapsule formation, surgical margin, and MVC were associated with overall survival; this result was statistically significant. Figure 2 shows disease-free and overall survival after hepatectomy compared with MVC. Discrimination of disease-free and overall survival was the most statistically significant when we used a cutoff level of 409/mm 2 . Disease-free survival rate was statistically significantly lower in patients with higher MVC compared with patients with lower MVC; furthermore, overall survival rates were also statistically significantly lower in patients with higher MVC. Table 4 shows the results of multivariate analysis for disease-free and overall survival after hepatectomy for various factors that showed statistically significant association by univariate analysis. A higher level of preoperative CEA level was associated with lower disease-free survival after hepatectomy, but this finding was not significant. On the other hand, poorly differentiated adenocarcinoma and higher MVC were identified as independent risk factors for lower overall survival after hepatectomy.
DISCUSSION
Tumor angiogenesis is closely associated with tumor aggressiveness and poorer prognosis in patients with primary liver tumors, and therefore, this biological characteristic seems essential to hepatic tumor progression. 14, 15 Preliminary results from our study and other studies reveal that tumor angiogenesis has a marked impact on prognosis in patients with MLC who undergo radical hepatectomy. 9, [13] [14] [15] [16] [17] In addition, the tumor hypervascularity is associated with lower patient survival rates. A variety of proangiogenic factors of liver metastasis have been identified, such as VEGF, Flk-1/KDR, and flt-1, which closely reflect tumor growth. 7, 9, 19 Angiogenesis facilitates metastasis formation by providing mechanisms to increase the likelihood of tumor cells entering the blood circulation and provides nutrients for growth at the tumor site. 19 Tumor angiogenesis can also be easily examined by means of immunohistochemistry, and therefore, we propose its use in the pathologic evaluation of hepatic tumors. From our clinical experience, MLC sometimes shows hypervascularity by the enhanced computed tomography or angiography, and we examined the relationship between the tumor enhancement pattern by means of computed tomography and MVC. However, we could not find any relationship between these two parameters by the preliminary data (not shown). We originally hypothesized that there was a relationship between MVC, vascularity, and histological differentiation because previous studies showed a correlation between tumor angiogenesis and depth of invasion, lymphatic infiltration, and lymph node metastasis in colorectal carcinoma patients with liver metastasis. 10, 20, 21 Our results showed that MVC was not associated with any clinicopathologic parameters of MLC, and the importance of increased MVC at the biologic level is still unknown. Although we also examined the significance of MVC in the intrahepatic cholangiocarcinomas, which have a similar morphology to MLC, no relationship with pathologic characteristics or patient prognosis after surgery was found. 22 On the basis of our preliminary data, 16, 17 we focused on the association between MVC and posthepatectomy outcomes, and therefore, we continued to add patients to the study and lengthened the follow-up period for these patients. In our analysis of survival, several associated tumor parameters, including MVC, were revealed on review of the surgical records, and these findings are in agreement with previous reports. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Since 1978, factors predictive of patient prognosis have been proposed by many investigators (Table 5) . [23] [24] [25] [26] [27] [28] [29] [30] [31] However, consensus has not yet been achieved at this stage. As shown in both our preliminary data and in our final results, higher MVC is associated with shorter disease-free periods and shorter overall survival times in patients with MLC undergoing hepatectomy. 16, 17 The multivariate analysis for patient prognosis, however, showed that only the preoperative CEA level was associated with disease-free survival, but this result was not statistically significant. No factors, including MVC, were considered independent risk factors of tumor-free survivals in the present study.
Previous reports showed that candidate factors associated with recurrence of MLC included intrahepatic lymphatic invasion, fibrous capsule formation, and oncogenes. 4, 32, 33 In a previous report, higher MVC was found to be independently associated with poorer prognosis. 31 MVC would seem to be a useful predictive marker for patient survival after hepatectomy in the present study. Miyagawa et al. also reported that high MVC was a statistically significant independent prognostic factor and was correlated with accumulation of liver macrophages in peritumoral regions. 34 Some immunoreactions to liver metastasis may affect tumor angiogenesis. VEGF expression, a proangiogenic factor, was a poor prognostic factor in colorectal liver metastasis, and MVC was closely correlated with VEGF expression. 35 Primary cancers with a high MVC formed high MVC liver metastases and primary carcinomas, and their liver metastases show common histological features. 36 Tumor vascularity may be correlated with proliferative activity or invasiveness of MLC. We plan to investigate this further as part of our future research. A biomarker-based approach yields marked benefits through informed treatment of resectable metastatic colorectal malignancy. Assessment and verification of multiple molecular markers including MVC may allow molecular profiling of metastases and tailoring of therapy according to the biological aggressiveness of individual tumors. The derivation of disease profiles is associated with disease recurrence and poor survival. 37 For future studies with longer follow-up periods, we plan to consider additional antiangiogenic treatment after hepatectomy. At this stage, some antiangiogenic drugs, including bevacizumab for colorectal liver carcinoma, have been developed and applied in the clinical setting. [38] [39] [40] [41] In cases were tumor angiogenesis is strongly associated with patient survival, antiangiogenic drugs could be used more aggressively. On the basis of our present findings, we hope to examine the survival benefit of adjuvant bevacizumab chemotherapy after radical hepatectomy to clarify the efficacy of MVC. MVC may become a selection marker in determining the need for adjuvant chemotherapy that uses antiangiogenic drugs.
In conclusion, we have demonstrated that higher MVC, as identified by CD34 antibody levels in MLC patients, is an independent predictor of overall survival in these patients. As a tumor biological factor, MVC (representing tumor angiogenesis) seems to be a practical alternative for predicting tumor recurrence and survival in patients with MLC. Furthermore, this factor can, we hope, be applied as a predictive marker in selecting antiangiogenesis treatments in the future.
